Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.

Slides:



Advertisements
Similar presentations
Kuala Lumpur, July 2nd 2013 The ANRS International VISCONTI Post Treatment Controller Cohort.
Advertisements

POSTER 82 CXCR4 using HIV-1 strains more abundant in PBMC than in plasma Chris Verhofstede 1 *, Linos Vandekerckhove 2, Veerle van Eygen 3, Kenny Dauwe.
Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
T follicular helper cells in HIV infection
Measuring the latent HIV Reservoir
Acute Retroviral Syndrome
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Natural and induced control of HIV infection: differences and similarities VISCONTI Study Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales.
High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
Impact of Early Initiation of Combination Antiretroviral Therapy on Measures of Virus in Peripheral Blood of Vertically HIV-1-Infected Children Jason Brophy.
Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.
Adj. Assistant Professor, UCLA Department of Medicine
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma Marcelin AG 1, Tubiana R 1, Lambert-Niclot.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
HIV Cellular Pathogenesis III
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine.
CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist Andre J Marozsan Progenics Pharmaceuticals, Inc.
The Berlin Patient and CCR5. Tim Brown: the only man to have been cured of HIV  Brown was diagnosed with HIV in 1995  11 years on antiretroviral therapy.
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Immunology of HIV Infection Michael F. Para, MD Professor of Internal Medicine Division of Infectious Diseases 1 1.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
HIV-1 infection decreases CD127 and PD1 expression on duodenal CD8+T cells Liliana Belmonte, PhD Academia Nacional de Medicina Buenos Aires, Argentina.
Gui-Qiang Wang Department of Infectious Diseases
Lessons Learned from Transient Remission Cases: Clues to Biomarkers of HIV Rebound Katherine Luzuriaga, MD University of Massachusetts.
Chelsea Harmon Catherine Hanson Abby Llaneza Jen Williams
What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.
ProteinStart position HLAEpitopePositive responses (n) Env209A*0101SFEPIPSHY1 Env310A*0101/Cw*0401GPGPGRAFY1 Gag406A*0302RAPRKKGC WK 1 Nef9A*0101/A*0302SVVGWPAVR1.
Immune reconstitution Anjie Zhen, PhD
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
Date of download: 5/28/2016 From: Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases Ann.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Background  HIV-1 infection persists in reservoirs and leads to progressive depletion of CD4+ T-cells even in subjects with slow disease progression 
Long-term clinical and viro-immunologic outcomes of post-treatment controllers (PTCs) in the ANRS-VISCONTI study Laurent HOCQUELOUX, MD Orléans’ Regional.
Immune system. Human immunodeficiency virus (HIV)
Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:
Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,
Expression Analysis of α4 integrin and related genetic polymorphisms in HIV acquisition and disease progression OF infected individuals Livia R. GóeS 1,
Basics of HIV Virus Vijay Kandula, MD MPH AAHIVS
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Viral and Host characteristics of a child with perinatal HIV-1 after prolonged period of ART cessation in the CHER trial Avy Violari, Mark Cotton, Louise.
Emory University School of Medicine Department of Medicine
HIV Cure: Current Status and Future Perspectives
Feedback meeting September 2017
Volume 36, Issue 3, Pages (March 2012)
Hiv.
Monique Nijhuis University Medical Center Utrecht, the Netherlands
Volume 140, Issue 2, Pages e1 (February 2011)
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non–genotype 1 infection by Julian Schulze zur Wiesch,
Quasispecies tropism and compartmentalization in gut and peripheral blood during early and chronic phases of HIV-1 infection: possible correlation with.
Immunodeficiency (2 of 2)
Double Trouble: HIV Latency and CTL Escape
Volume 36, Issue 3, Pages (March 2012)
Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.
Keep control: Elite and post-treatment controllers
Presentation transcript:

Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U. 1, Hauber I. 2, Hauber J. 2 1 University Medical Center Hamburg Eppendorf, Infectious Diseases Unit and 2 Heinrich Pette Institute - Leibniz Institute for Experimental for Virology, Hamburg, Germany; Conclusions: This case shows that a functional cure may be achieved in individual cases after early treatment of HIV infection. Broad HIV specific T cell responses seem to be associated with post treatment control of viral replication. No beneficial HLA haplotypes were detected in this patient. Further reading: Ein Mitglied der We thank the patient who participated in this study and Kristina Colberg for technical help.This work was supported by the German Center for Infectious Diseases (DZIF). Acknowledgements 98: HIV AB- 7/99: check up at primary physician: in good health 7-8/99 Africa trip, sexual transmission most likely 9/99 acute viral illness/lymphadenopathy 9/99 HIV-ELISA: Ab + (WB: few bands, immunfluorescence neg) 10/99 start ART (AZT/3TC/EFV, later switched to TDF/FTC/EFV 5/04 STI HLA-A: 01/02, HLA-B: 44/52 CCR5-Promotor variant: Homozygous A59029G Figure 1 (clinical course): Here, we present data of unique case of a post treatment controller with undetectable viral loads after early ART treatment was stopped after 5 years in Remarkably, the viral load of this patient has stayed below the level of detection with stable CD4+ counts for more than nine years. This patient was further analyzed for host factors but neither the HLA molecules (HLA A 01,02, B44, B52) nor a deletion of the CCR5 receptor could account for the control of the virus after treatment interruption. No viral RNA was detected at any time point later than 3 mths. post STI using ultrasensitive assays and no proviral DNA was found in PBMC. Colon biopsies were staining negative for p24 Ag and no viral RNA was found in CSF. No viral replication was detected after ex vivo stimulation of PBMC using standard techniques. However, virus was recovered using prolonged ex vivo stimulation with repeated addition of stimulated donor cells. HIV replication was detected after transplanting the patient`s CD4+ T cells into Rag2-/-γc-/- (Rag-hu) humanized mice indicating replication competent virus. Sequencing of these viruses is currently ongoing, preliminary analysis shows CCR5 co-receptor usage. Clinical course: Background: Early initiation of cART during acute HIV infection can lead to control of viral replication after cessation of therapy in a rare subgroup of patients termed post treatment controllers (PTC). We set out to define immunological and virological correlates of post treatment control and to assess the potential of eradication vs. functional cure. Methods: A 67 yrs. old male was treated with cART ca. 3 months after HIV exposure and 1 month after seroconversion for a total of 5,5 yrs.; cART was stopped in May 2004 and the patient remained BLOD(< 20 c/ml) and shows normal T cell counts and distribution without ART since 9 years. We performed comprehensive analyses to assess the immuno-virological correlates of PTC including a humanized mouse model in this patient. Results: CD4 count is stable between cells/µl, the homozygous CCR5 promoter variant A59029G but no delta 32 deletion was detected, HLA-I subtype was A 01, 02 B: 44, 52; no viral RNA or DNA was detected using ultrasensitive techniques in plasma or PBMC. ELISPOT revealed broad CTL responses against gag and nef epitopes and we could detect HIV specific CD4 proliferative responses. We find a normal distribution of TEM and TCM comparable to a control group of nine elite controllers (EC) (data not shown). The frequency of peripheral Treg cells was comparable to normal controls and EC (data not shown). Eventually virus could be recovered in vivo in a Rag2 -/- γc -/- (Rag-hu) humanized mouse model after transplantation of purified donor CD4 T cells and anti CD3/CD28 stimulation indicating the persistence of replication competent virus (data not shown). Conclusion: The data obtained in this unique case suggest a functional cure of this patient rather than viral eradication after early onset cART. The presence of strong HIV specific T cell responses, normal frequency of regulatory T cells and animal data suggest a strong role of preserved adaptive immune responses as a correlate of viral control in this patient. Subsequent virological and immunological studies should look into the correlate of viral control in this and other PTC patients. Figure 3: Strong proliferative HIV-specific CD4+ T cell responses can be detected in the standard CFSE proliferation assay. Figure 2: Broadly directed CD8+ T cell responses can be detected in a standard Elispot assay using HIV CD8+ optimal peptides. Results: Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study, Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand- Fenoel V, Girault I, et al. (2013) Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathog 9(3): e doi: /journal.ppat Abstract: